60
I
Working purties
I
WP4/29
GENE
TRANSFER
(HCC)
CELLS
INTO IN
ASSOCIATED D
Pew.
Y
Spain
rAAV
virill
are
and
amactive
efficiency Up
rAAV dlffercnr
stratep~s
Materials
and
IacZ
gene
HCC
cell
under
ceils
formed
investigated
the
of
etoposide
treatment
expression
was
determined
analysis.
Results:
We
increased
about
26-fold,
cells
DNA
synthesis
with
inhIbitor
on
etoposlde cfficxncy
that obtamed
with
injection not
transient inoculation. rranduccd findings
1
WP4/30
X-gal that
the
help. was
able
that
up to
Our
that rAAV
in viva IO-20%
However, of
of
improve cells
intratumor tumor
results
indicate
that
after
y-irradiation
rAAV
diffuses
can be used as a vector
be
of Hep
3B
increased
rAAV
for gene
as
local
transduction
at the site
of vector
of etoposide because
after HCC
level
that previous
probably
rapidly
can
etoposide
injection
cells,
rAAV
at the same
showed
which with
of
gene
FACS-Gal
and topoisomerase
with
HCC
We and
LacZ and
treatment
expression
studies
tumor
mice.
rAAV.
previous 38
HCC
nude
staining
y-irradiation
of Hep
human
hydroxyurea
efficiency
by
by
carrying
to infect
in
of
to substantially
efficiency
and in viva
subcutaneous
of IacZ
Our
used
y-irradiation,
90-fold
Treatment
ctoposide
in viva
hydroxyurea,
vectors.
plasmid
was
transduction
and
these
rAAV
efficiency
explored
was constructed
and an AAV
immunochemical
and the intensity
Conclusion: suggests
help,
transfer
have
with
gene
or
use of
gene
we
efficiency
38
be
make
as adenovirus
and
Hep
to
the potential
investigated
rAAV
of
transduction
by
the transgcne. of
in wtro
injection
inhibitor
transduction
cffcct
the
41sfold
a way
exprcsscd
promoter.
adenovirus
adcnowrus
in such
mcrcase
plasmid
appear
its use is the low
such
reponer
and to transduce
found
of the tumor
efficiency,
a helper
rcspecuvcly.
transduction y-madinnon
IacZ
subcutaneous
effect
have
transduction
of CMV
it1 YWO
after
We using
conrainmg
with
the control
lmc (Hep3B)
nodules
Aims:
to enhance
virus
M. Rahmani. B. Lardeux. F. Nadori, D. Bemuau INSERM U 327, FacultC de MCdecine X. Bichat, Paris, France.
properties
limits
concerning
iu viva
and
They these
which
a helper
ijr viva.
rAAV
293
of
cells
m order
of
absence
of Navarra,
DNA.
Although
a barrier
is no information
hlcthods:
cotransfcctlon
ADENO-
, University
strand
viva
there I,{ vim
culls
single in
vectors,
in the
liver
I” HCC
HEPATOCYTE GROWTH FACTOR (HGF)-INDUCED ACTIVATION OF THE AP-1 COMPLEX : A COMPARISON BETWEEN NORMAL AND TRANSFORMED RAT HEPATOCYTES.
CARCINOMA
RECOMBINANT
School
of
stably
therapy
to now
to transduce
efficiency
persist
as gene
herpesvirus.
Medical
composed
can
transduction
USING
J Prieto.
Medicine,
vectors
noncytopathlc
HEPATOCELLULAR
VII’0
IN
(rAAV) Sun.
of lmernal
Pamplona.
rAAV
AND
VIRUS
C. Ghan.
Department
HUMAN
VITHO
its can
did
of
the
intratumoral be
efticiently
of tumor
cells.
therapy
ofHCC.
These
The response of normal and transformed hepatocytes to HGF has been shown to differ, suggesting that different signal transduction pathways are triggered by this growth factor in normal and transformed cells, Activation of the Fos/Jun AP-1 dimeric transcription factor is a key event of the cell response to growth factors. We have therefore compared HGF-induced activation of AP-1 in normal and transformed rat hepatocytes, the 7777 cell line. In both cell types, increased DNA-binding activity to an AP-1 probe was induced 2-6h after HGF stimulation and it was completely prevented in the presence of cycloheximide. Analysis of the type of Fos and Jun proteins recruited to the AP1 dimers after HGF activation indicated differences in the
composition of the HGF-induced DNA-binding complexes in the 2 cell types. While Fra-1 containing dimers were present in both cell types, c-Jun- and c-Fos-containing complexes were detected in hepatocytes and 7777: cells, respectively. Very close patterns of induction of the fos and jun genes at the mRNA level were found in the 2 cell types with a rapid (30 min) and transient accumulation of c-fos, fosB, c-jun and junB mRNAs. However, induction of the genes at the protein level differed: c-Jun, JunB and Fra-1 accumulated in both cell types, but c-Fos levels increased only in 7777 cells. These results show that the patterns of AP-1 activation by HGF differs between normal and transformed hepatocytes. The differences are mainly at the traductional and post-traductional level, leading to the recruitment of different Fos/Jun proteins into the AP-1 dimers.
1
ENHANCED AND STABLE INTEGRATION OF PLASMID DNA INTO THE GENOME OF LIVER CELLS BY NON-VIRAL GENE TRANSFER VIA ADENO-ASSOCIATED VIRUS INVERTED TERMINAL REPEATS R. Steiaemald. W.H. Caselmann*. M. Alt. MPI f. Biochemie, Dept. of Virus Research, Martinsried, *Dept. of Medicine, University of Bonn, Germany Since most gene therapy strategies require permanent expression of transgenes, integrating vectors like recombinant adeno-associated virus (AAV) have been developed. The aim of this study was to adapt the highly effective mechanism of integration of AAV to plasmid DNA, which can easily be combined with tissue-specific non-viral vector systems, e.g. for liver gene therapy. HepG2 cells were transfected with plasmids containing the neomycin resistance gene flanked by the inverted terminal repeats (ITRs) of AAV. the only &-active elements required for integration of AAV. ITR and control plasmids integrated randomly at low rates, as deduced from the number of resistant colonies. This result as well as the transient expression of different reporter genes indicate that the plasmids do not persist episomaly. To improve integration efficiency, plasmids containing the rep gene of AAV were constructed. Rep is the mediator of site-specific integration of wildtype AAV into human chromosome 19. In the presence of Rep, integration efficiency of ITR plasmids increased about eightfold. The site specificity of integration of these plasmids is evaluated by Southern-blot analysis. These data provide evidence that non-viral gene transfer using AAV ITRs can efficiently be used to integrate plasmid DNA into the hepatocyte genome.
REGULATION
OF HGF GmEEXPRIZZION
BY ‘IGF-01
Liver Unit and Department Molecular Medicine, King’s College School of medicine and Dentistry, London, UK Introduction Transforming growth factor-01 (TGF-l31) inhibits Hepatocyte growth factor (HGF) secretion by fibroblasts and reduces the expression of the full length 6.0 kb HGF mRNA transcript by an unknown mechanism. The effect on the alternatively spliced 1.5 kb HGF gene transcript, which encodes the HGF antagonist protein HGF-NK2, has not been reported. Methods and Results The effect of TGF-Dl on HGF gene expression was investigated in MRC-5 cells, using Northern blot analysis. TGF-I31 inhibited expression of the 6.0 kb HGF mRNA in a dose dependent manner and at 1 @ml for 24 hours reduced levels to only 7% of control values, whereas there was little effect on the 1.5 kb HGF-NK2 mRNA. The fall in the 6.0 kb mRNA species was apparent at 3 hours, was maximal by 9 hours, persisted up to 36 hours and recovered to basal levels at 48 hours; it required TGF-I31 to be present for only the first 2 hours. Using actinomycin D to block RNA synthesis, it was observed that TGF-I31 increased the rate of degradation of the 6.0 kb HGF mRNA transcript but had little effect on the stability of the 1.5 kb HGF-NK2 mRNA. TGF-81 had no effect on HGF promoter activity in MRC-5 cells transiently transfected with a chloramphenicol acetyltransferase (CAT) reporter plasmid containing HGF gene 5’-flanking sequences and ribonuclease protection mapping demonstrated that TGF-I31 had no effect on the relative use of the transcription initiation sites. Conclusion The differential effect of TGF-I31 on expression of the alternatively spliced HGF mRNA transcripts in MRC-5 cells is mediated at the post transcriptional level and favours production of the truncated HGF antagonist protein.